In overweight patients with non-alcoholic fatty liver disease Saroglitazar is able to improve transaminases but not liver stiffness measurement and controlled attenuation parameter unless accompanied by weight reduction
EASL LiverTree™, Prateek Padole, 226714
Influence of Hypothyroidism on Insulin Resistance and Adipokine Profile in Patients with Nonalcoholic Fatty Liver Disease
EASL LiverTree™, Vasyl PRYSYAZHNYUK, 226715
RNase MCPIP1 regulates hepatic PPAR gamma via TXNIP/PGC 1-alpha pathway
EASL LiverTree™, Natalia PYDYN, 226716
Insulin secretion is directly related to NASH, fibrogenesis and fibrosis in Non-diabetic patients with Non-Alcoholic Fatty Liver Disease
EASL LiverTree™, Chiara Rosso, 226717
Round-table discussion & Consensus Statement III: How should we manage patients with NAFLD/NASH in 2018? What lifestyle advice should we give?
EASL LiverTree™, Session Speakers, 231716
Consideration of metabolic surgery and metabolic endoscopy?
EASL LiverTree™, Sigal Fishman, 227265
Clinical Case IV - illustration of evolution of case to cirrhosis to include T2DM and rising weight
EASL LiverTree™, Elisabetta BUGIANESI, 227264
Lifestyle management including nutrition and exercise
EASL LiverTree™, Mathias Plauth, 227263
Clinical Case III - case showing evolution to confirmed NASH
EASL LiverTree™, Elisabetta BUGIANESI, 227262
The NLRP3 antagonist IFM-514 decreases fibrosis and inflammation in two mousemodels of non-alcoholic steatohepatitis (NASH)
EASL LiverTree™, Fernando Magdaleno Verduzco, 226648
Human PNPLA3 I148M gene variant impairs secretion of polyunsaturated VLDL-TG and resembles the catalytically inactive PNPLA3 variant in mice
EASL LiverTree™, Panu Luukkonen, 226647
Activating the Hormonal Effect of miR-122 Reverses NASH
EASL LiverTree™, Chofit Chai, 226646
Effect of sebelipase alfa on liver parameters over 96 weeks in a diverse population of children and adults with lysosomal acid lipase deficiency
EASL LiverTree™, Florian Abel, 226645
Round-table discussion & Consensus Statement I: - Assessing patient symptoms in NASH in trial and in practice
EASL LiverTree™, Session Speakers, 231715
Patient Reported Outcome Measures - the regulatory perspective
EASL LiverTree™, Elmer Schabel, 227255
Role of patient organizations in progression from NAFLD to NASH and further
EASL LiverTree™, Marko Korenjak, 227254
Patient reported outcome measures in NASH and science behind the symptoms
EASL LiverTree™, Zobair Younossi, 227253
How patients feel: Assessing symptoms in patients with NASH: Chair
EASL LiverTree™, Salvador AUGUSTIN, 227251
Sheep as a large animal model for fatty liver research
EASL LiverTree™, Hay Dvir, 226691
The effect of carvedilol compared to propranolol to control hepatic venous pressure gradient (HVPG) in cirrhotic patients with portal hypertension: an evident based case report
EASL LiverTree™, Afifa Fahriyani, 226692
Association between NAFLD, cardiovascular complications, insulin resistance in obese patiens
EASL LiverTree™, Iryna FEDZHAGA, 226693
Histidine rich glycoprotein as a hypoxia-induciblefactor 2α – dependent pro-fibrogenic mediator in experimental non-alcoholicfatty liver disease.
EASL LiverTree™, Beatrice Foglia, 226694
Automated quantitation of ballooning, inflammation, steatosis and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD
EASL LiverTree™, Roberta Forlano, 226695
Pharmacological inhibition of Adipose Triglyceride Lipase prevents metabolic disorders in mice
EASL LiverTree™, Gernot Grabner, 226696
Human induced pluripotent stem cell derived hepatocyte like cells - a valuable model for drug testing in Nonalcoholic Fatty Liver Disease
EASL LiverTree™, Nina Graffmann, 226697
C-MYC overexpression in hepatocytes is responsible for the spontaneous development of murine non-alcoholic steatopatitis
EASL LiverTree™, Feifei Guo, 226698
Hepatocyte-specific caveolin-1 in non-alcoholic steatohepatitis mouse models.
EASL LiverTree™, Mei Han, 226699
The association between visceral fat and evolution of patients with nonalcoholic fatty liver disease
EASL LiverTree™, Marta Hernandez Conde, 226700
Combination of GLP-1 agonist and SGLT2-inhibitor improves the non-alcoholic steatohepatitis in a high fat-high fructose mice model for NASH
EASL LiverTree™, Katharina Luise Hupa, 226701
Steatotic zebrafish larva to evaluate mechanisms involved in NAFLD progression induced by a mixture of alcohol with an environmental pollutant, benzo[a]pyrene
EASL LiverTree™, Muhammad Imran, 226702
Restoration of Mitochondrial Respiratory Chain Activity by RIP3 Depletion in Experimental NAFLD
EASL LiverTree™, Tawhidul Islam, 226703
State-of-the-art: Carcinogenesis in NASH
EASL LiverTree™, Jessica Zucman-Rossi, 227250
Best animal models for NASH research - view from industry
EASL LiverTree™, Keld Fosgerau, 227249
Mechanisms of fibrogenesis in NASH
EASL LiverTree™, Detlef SCHUPPAN, 227248
Gut and the liver
EASL LiverTree™, Herbert Tilg, 227247
Insulin resistance and lipotoxicity
EASL LiverTree™, Amalia Gastaldelli, 227246
Cumulative effects of Western diet and alcohol abuse: a novel experimental mouse model of NASH/ASH-derived liver injury
EASL LiverTree™, Raquel Benedé, 226677
Multiplex real-time PCR detection of variants in the PNPLA3 and TM6SF2 genes associated with non-alcoholic fatty liver disease
EASL LiverTree™, Anne Berndt, 226678
Genetic assessment of the role of bile acids in children affected by non-alcoholic fatty liver disease
EASL LiverTree™, Teresa Brunetti, 226679
An open label randomized controlled trial of Vitamin D vs Pentoxifylline in non-diabetic patients of Nonalcoholic fatty liver disease
EASL LiverTree™, Sanchit Budhiraja, 226680
An Integrated Primary and Secondary Care Algorithm for Evaluating Non-Alcoholic Fatty Liver Disease Significantly Increases Community Screening for Hepatitis B and C Infection
EASL LiverTree™, Richard J Aspinall, 226681
Who cares about NASH? Patients with NAFLD care!
EASL LiverTree™, Koya Ayonrinde, 226682
Multi-parametric MRI as a composite biomarker for NASH and NASH with fibrosis
EASL LiverTree™, Velicia Bachtiar, 226683
RIPK3-MLKL mediated necroptosis contributes to ischaemia induced cell death in steatotic hepatocytes
EASL LiverTree™, RAJI BAIDYA, 226684
Energy metabolism in obesity reveals that NASH requires targeting AMPK/mTOR-driven pathways
EASL LiverTree™, Noemí Cabré, 226685
Exercise improves HFD-mediated metabolic syndrome, dysbiosis and associated gut-liveraxis and biliar acid deregulation in an in vivo model of early obesity and NAFLD
EASL LiverTree™, Sara Carbajo-Pescador, 226686
The Zucker Diabetic Sprague Dawley rat: a novel model for Type 2 diabetes-related non-alcoholic steatohepatitis
EASL LiverTree™, Rachael Dangarembizi, 226687
Ultrasound-based quantitative assessment of hepatic fat content: the Seato-score system
EASL LiverTree™, Nicole Di Lascio, 226688
Changes in liver fatty acid delta-9, delta-6 and delta-5 desaturase activities in two animal models of hepatic steatosis
EASL LiverTree™, Laura Giuseppina Di Pasqua, 226689
The deletion of perforin protects from non-alcoholic steatohepatitis (NASH) development
EASL LiverTree™, Hannah Drescher, 226690
Effect of Silybin onfibrogenesisin an in vitro model of NASH
EASL LiverTree™, Beatrice Anfuso, 226663
Dietary wheat amylase trypsin inhibitors worsen chronic liver disease in pre-clinical models of NASH and liver fibrosis
EASL LiverTree™, Muhammad Ashfaq Khan, 226664
Does oleuropeininduce apoptosisor autophagic processes in HFD mice?
EASL LiverTree™, Clara Balsano, 226665
Lean versus overweight/obese non-alcoholic fatty liver disease - a clinicopathological comparative study
EASL LiverTree™, Sanchit Budhiraja, 226666
Liver microcirculation disorders and its correction by Hepa-Merz at the nonalcoholic steatohepatitis.
EASL LiverTree™, Tatiana Ermolova, 226667
Clinical impact of comorbidities in NAFLD patients referred in a tertiary centre in Italy
EASL LiverTree™, Antonio Liguori, 226669
Algorithm to identify patients with an activity grade >2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD) Development in a large prospective multicenter UK study
EASL LiverTree™, Philip N Newsome, 226670
DGAT2 inhibition improves endpoints associated with NASH pre-clinically
EASL LiverTree™, Trenton Ross, 226671
Hypercoagulopathy risk factors in liver cirrhosis patients dueto non-alcoholic steatohepatitis
EASL LiverTree™, Nataliya Virstyuk, 226673
Non-alcoholic steatohepatitis: an independent risk factor for albuminuria in non-diabetic patients
EASL LiverTree™, Ming-Hua Zheng, 226674
Prevalence of de novo metabolic syndrome and its risk factors in a liver transplanted population: a prospective study
EASL LiverTree™, Chiara Becchetti, 226676
An obese mouse model of diet-induced NASH with biopsy-confirmed advanced fibrosis and progressive tumor development
EASL LiverTree™, Michael Feigh, 230985
Promises and limits of non-invasive methods in NASH
EASL LiverTree™, Jérôme Boursier, 227241
Clinical Case II - evolution of identified case + use of non-invasive modalities
EASL LiverTree™, Emmanuel Tsochatzis, 227240
Case identification in diabetes clinics : where do we stand so far ?
EASL LiverTree™, Roy Taylor, 227239
Clinical Case I - how do cases present in the community+ Exemplar case illustrating challenge how to decide which patients need specialist input
EASL LiverTree™, Emmanuel Tsochatzis, 227238
Anti-fibrotic properties of OCA and INT-767 in an in vitro model of NASH
EASL LiverTree™, Beatrice Anfuso, 226649
Deletion of IL-4 Receptor alpha on macrophages attenuates inflammation and fibrosis in murine nonalcoholic steatohepatitis (NASH)
EASL LiverTree™, Muhammad Ashfaq Khan, 226650
HFD mouse model displays altered copper-related gene expression
EASL LiverTree™, Clara Balsano, 226651
Cytokeratin 18 fragment level is a useful biomarker in predicting steatosis and NASH but not fibrosis
EASL LiverTree™, Sanchit Budhiraja, 226652
Endothelial disfunction as a mechanism of the hepatic microcirculation disorders and its correction at the nonalcoholic steatohepatitis patients.
EASL LiverTree™, Tatiana Ermolova, 226653
Genetic susceptibility to increased intestinal permeability is associated with diabetes and progressive liver disease in patients with non-alcoholic fatty liver disease (NAFLD)
EASL LiverTree™, Antonio Liguori, 226655
Comparison of FS3 with different biomarkers to identify patients with active NASH (NAS>=4) and advandced fibrosis (F>=2)
EASL LiverTree™, Philip N Newsome, 226656
ACCi / DGAT2i combination therapy for the treatment of NASH
EASL LiverTree™, Trenton Ross, 226657
Effects of Pioglitazone and L-ornithine-L-aspartate Long Therapy on NASH course in Patients with Diabetes Mellitus Type 2
EASL LiverTree™, Nataliya Virstyuk, 226659
Development of a novel nomogram to detect significant liver fibrosis in biopsy-proven non-alcoholic fatty liver disease
EASL LiverTree™, Ming-Hua Zheng, 226660
A Gut Hormone Can Play A Role in NAFLD
EASL LiverTree™, Mohamed Abdel-Samiee, 226661
Increased liver expression of Vitamin D Receptor is associated with NAFLD, visceral obesity and adipose tissue inflammation
EASL LiverTree™, Ilaria Barchetta, 226662
The clinical picture of NAFLD/NASH: Round-table discussion
EASL LiverTree™, Session Speakers, 227235
The current policy on NAFLD in Europe - results from the EILF NAFLD policy review
EASL LiverTree™, Frank Tacke, 227234
Natural history and use of large data to risk stratify
EASL LiverTree™, Quentin Mark Anstee, 227233
Paediatric NAFLD: the future burden of NASH including the risk of HCC linked to obesity during childhood
EASL LiverTree™, Valerio Nobili, 227232
Health care burden of NAFLD and NASH
EASL LiverTree™, Jacob George, 227231
Global overview of obesity and population strategies to tackle it
EASL LiverTree™, Harry Rutter, 227230
Welcome and introductory remarks
EASL LiverTree™, Prof. Frank Tacke & Philip N. Newsome, 233814
Subclinical T cell-mediated liver transplant rejection: The jury is still out
EASL LiverTree™, James A. Hutchinson, 234456
Feeding the Hedgehog: A new meaning for JNK signalling in liver regeneration
EASL LiverTree™, Concetta Bubici, 234457
Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C
EASL LiverTree™, Stephen Bloom, 234458
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
EASL LiverTree™, Markus Cornberg, 234459
HCV modifies EGF signalling and upregulates production of CXCR2 ligands: Role in inflammation and antiviral immune response
EASL LiverTree™, Johannes Georg Bode, 234460
Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients
EASL LiverTree™, Xavier Forns, 234461
Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis
EASL LiverTree™, Aldo J. Montano-Loza, 234462
Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis
EASL LiverTree™, Vinay Sundaram, 234463
CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis
EASL LiverTree™, Xiaogang Du, 234472
Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies
EASL LiverTree™, Nick SHERON, 234473
Hepatic manifestations of telomere biology disorders
EASL LiverTree™, Douglas Simonetto, 234474
Hepatopulmonary syndrome
EASL LiverTree™, Valentin Fuhrmann, 234475
The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis
EASL LiverTree™, Candid Villanueva, 234476
Reply to: “Relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis”
EASL LiverTree™, Filippo Schepis, 234477
Influence of ablation technique on treatment failure for perivascular hepatocellular carcinoma
EASL LiverTree™, Jean-Yves Mabrut, 234478

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings